By CapitalSnitch Research Desk · updated Oct 11, 2026 · data from SEC filings and official Congress disclosures
Over the last 12 months, two PharmaCyte Biotech, Inc. the people running the company purchased shares at market prices, about $128,000 in total, and none of them sold.
The largest purchase came from Silverman Joshua (CEO), about $33,000. That includes C-suite money, which tends to get the most attention.
No open-market insider buying or selling in the last full quarter. Insiders bought in 1 of the last 7 full quarters. Big money check: 28 institutions held PMCB as of Q2 2026, and more funds sold than bought.
Are insiders buying or selling PMCB stock?
In the last 12 months PharmaCyte Biotech, Inc. insiders made open-market purchases worth about $128,000 and sales worth about $0. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
When was the last insider trade in PMCB?
The most recent open-market insider trade in PMCB was filed on 2026-01-07.
How many institutions own PMCB?
28 investment managers reported holding PMCB in SEC Form 13F filings for Q2 2026.
Has any member of Congress traded PMCB?
No congressional trades in PMCB were reported in the past two years. The full list is free on CapitalSnitch.
Free weekly email: the week's biggest insider buys and Congress trades, every Monday. No spam, one-click unsubscribe.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1).
Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).